

# **CLINICAL RESEARCH & MEDICAL AFFAIRS**

**EPIDEMIOLOGY AND BIOSTATISTICS**

**Faculdade de Ciências Médicas da Santa Casa  
São Paulo – Brasil**

**Prof. Dr. Ruben Sciuto**  
**MD Medical Statistician Consultant**  
**[www.sciutoestatisticamedica.com.br](http://www.sciutoestatisticamedica.com.br)**



# Prof. Dr. Ruben Sciuto

## Track Record

- 2009 – 2019** Biostatistician consultant and director of the company **SCIUTO STAT CONSULTING**, São Paulo, Brazil. <http://www.sciutoestatisticamedica.com.br>
- 2014– 2019** Senior Medical Statistician Consultant in the **RIGHT CONCEPT ASSOCIADOS**, São Paulo, Brazil.
- 2006–2019** Statistical Consultant at **CLINICAL LABORATORY EMERGENCY** "Hospital de Clínicas", and the journal of the **URUGUAYAN SOCIETY OF CLINICAL PATHOLOGY**, Montevideo-Uruguay.
- 2007–2008** Professor of Biostatistics, **DEPARTMENT OF BIOSTATISTICS**, Faculty of Agronomy of Uruguay (UDELAR).
- 2003–2006** Statistical and Methodological Advisor, **DEPARTMENT OF CARDIOLOGY** at "Hospital de Clínicas" and **DEPARTMENT OF PNEUMOLOGY** at "Maciel Hospital" of Montevideo-Uruguay
- 1997–2004** Professor of Medical Statistics, **DEPARTMENT OF QUANTITATIVE METHODS**, Faculty of Medicine of Uruguay (UDELAR).
- 2001** MD (Medical Doctor), PhD in General Medicine graduated from the Faculty of Medicine, University of the Republic (UDELAR) Montevideo - Uruguay.



# **Biostatistics applied to clinical research and health sciences**

**Prof. Dr. Ruben Sciuto**  
**MD Medical Statistician Consultant**  
**[www.sciutoestatisticamedica.com.br](http://www.sciutoestatisticamedica.com.br)**



# STATISTICS $\neq$ MEDICAL STATISTICS

**STATISTIC**

**BIOSTATISTIC**

**MEDICAL  
STATISTICS**

# MAPPING & STATISTICAL ORGANIZATION

## 1. DESCRIPTIVE STATISTICS

## 2. PROBABILITY & PROBABILITY DISTRIBUTIONS

## 3. INFERENCE STATISTICS

- STATISTICAL ESTIMATION THEORY
- STATISTICAL DECISION THEORY.
- STATISTICAL MODELS THEORY.


# WHAT IS THE IMPORTANCE OF KNOWING THE MAIN STUDY DESIGNS AND STATISTICAL TESTS RELATED TO CLINICAL RESEARCH?

- Acquire knowledge to create clinical research (Clinical Research Engine).
- Appropriate bibliographic survey and adequate understanding of the scientific literature (evaluate, criticize and discuss).
- Apply the appropriate statistical tests and risk measures according to the type of study.
- Know the limitations of each type of study.
- Know the advantages and disadvantages of each type of study.



# SCIENTIFIC EVIDENCE OF WHAT?

EVIDENCE OF THE  
**CAUSATION** OF A  
FACTOR (EXPOSURE)  
RELATED  
WITH A ENDPOINT





# QUALITY OF SCIENTIFIC EVIDENCE



**MINIMIZE**

- **ERRORS**
- **BIAS**
- **CONFOUNDERS**





# MINIMIZE: ERRORS, BIAS AND CONFOUNDERS

## ➤ **RANDOM ERROR**

The measurements are almost always in subjects and there may be random variations. To minimize random error it is necessary to calculate a suitable sample size.

## ➤ **BIAS**

Caused by systematic error: in the selection of patients, measurement of results (clinical scales, laboratory analyzes, etc.), statistical analysis of data, interpretation of results and other tendentious conducts in all clinical research.

## ➤ **CONFOUNDERS**

Factors that affect the interpretation of results. This is another variable (taken into account or not in the study), however it was not considered in the analyzes and may be affecting the true value or meaning of the "factor - outcome" relationship.



# WHAT EXACTLY DO YOU INTEND TO DO?

## PICO

**P** – who are the **patients** or what's the **problem**?

**I** – what is the **intervention** or **exposure**?

**C** – what is the **comparison** group?

**O** – what is the **outcome** or **endpoint**?

Population (P)

Interventions (I) or Exposures (E)

Outcomes (O)

Centre for Evidence Based Medicine, Oxford, UK [www.cebm.net](http://www.cebm.net)



# WHAT EXACTLY DO YOU INTEND TO DO?

## PATIENTS

- Disease or condition
- Stage, severity
- Demographic characteristics (age, gender, etc.)

## INTERVENTION

- Type of intervention or exposure
- Dose, duration, timing, route, etc.

## COMPARISON

- Risk or treatment
- Placebo or other active treatment

## OUTCOME

- Frequency, risk, benefit, harm
- Dichotomous or continuous
- Type: mortality, morbidity, quality of life, etc.



# ARE YOU GOING TO OBSERVE OR EXPERIMENT?

## OBSERVATIONAL

*Cross sectional, case series, case-control studies and cohort studies.*

- identify participants
- observe and record characteristics
- look for associations

## EXPERIMENTAL

*Before and after studies, comparative trials (controlled or head to head), randomised trials .*

- identify participants
- place in common context
- intervene
- observe/evaluate effects of intervention



# LEVELS OF THE SCIENTIFIC EVIDENCE

## WHAT DEFINES THE LEVEL OF THE SCIENTIFIC EVIDENCE OF A STUDY?

The main "**sources of errors**", that define the level of evidence!

### ➤ Related to study design aspects

- a) Different types of biases: information, selection, inclusion, etc.
- b) Confounders.
- c) Variability: biological, instrument, temporal, etc.

They are related to the **INTERNAL VALIDITY**: to measure properly what has to measure ...

### ➤ Related to the statistical (inferential) aspects

- a) Power of study.
- b) Level of significance of the study.
- c) Use of appropriate tests and estimators.
- d) Adequate samples size .


They are related to **EXTERNAL VALIDITY**: generalization of results to the population ...



# CLINICAL RESEARCH DESIGN

| No intervention  |   | Intervention                                     |  |
|--|---|--|--|
| Observational  |   | Experimental                                     |  |
| Comparison group   |   | Random Allocation                                |  |
| Yes  | No  | Yes  | No   |
| <b>Analytical Study</b> <ul style="list-style-type: none"><li>• Case-Control Study<br/>(<i>Outcome → Exposure</i>)</li><li>• Cohort Study<br/>(<i>Exposure → Outcome</i>)</li><li>• Cross Sectional Study<br/>(<i>Exposure and Outcome at the same time</i>)</li></ul> | <b>Descriptive Study</b> <ul style="list-style-type: none"><li>• Prevalence Study<br/>(Cross Sectional Study)</li></ul> | <b>Randomized<br/>Controlled Trial<br/>(RCT)</b> | <b>Non – Randomized<br/>Controlled Trial</b> <div data-bbox="2216 1246 2504 1403"></div> |

# CLINICAL RESEARCH DESIGN





# LEVELS OF SCIENTIFIC EVIDENCE

## Level I

- \* Systematic review (SR) and Meta-Analysis of Randomized Controlled Trials (RCT)
- \* Randomized Controlled Trials

## Level II

- \* Systematic review of Cohort Studies
- \* Cohort Studies
- \* Poor quality RCT

## Level III


- \* Systematic review of Case-Control Studies
- \* Case-Control Studies
- \* In-vitro Studies

## Level IV

- \* Case Series
- \* Cross-sectional studies
- \* Poor quality case control studies

## Level V

- \* Case Reports
- \* Expert opinion/Literature review.



# LEVELS OF SCIENTIFIC EVIDENCE

## PRIMARY STUDIES

- Case Series
- Cross-sectional studies
- Case-control studies
- Cohort Studies
- Randomized Controlled Trials

UNFILTERED  
INFORMATION

## SECONDARY STUDIES

- Narrative reviews
- Systematic reviews (SR)
- SR and pairwise meta-analysis
- SR and network meta-analysis

## TERTIARY STUDIES

- Meta epidemiologic studies
- Overview of reviews
- Umbrella reviews

FILTERED  
INFORMATION



# LEVELS OF SCIENTIFIC EVIDENCE

**BIAS**: is the difference between study result and truth

**THE BEST EVIDENCE**: is the evidence most likely to provide an unbiased view of the truth.

❖ Of course, we can never know the truth, but we can try to come as close as possible by performing and using **well-designed** and **well executed studies**.



**David Lawrence Sackett.**

November 17, 1934, Chicago, Illinois, United States, May 13, 2015, Markdale, Ontario, Canada. was an American-Canadian medical doctor and a pioneer in evidence-based medicine.

He is known as the fathers of Evidence-Based Medicine.


In 1994, he moved to the University of Oxford in England to establish the International Centre for Evidence-Based Medicine.



# LEVELS OF SCIENTIFIC EVIDENCE

## The EBM triad

- Safety and efficacy evidence
- RCT
- Cohort studies
- Case-control studies



- Clinical expertise
- Follow-up
- Therapy
- Prediction
- Clinical knowledge

- Education
- Confidence
- Recovery
- Less pain
- Rehabilitation



# The Oxford Centre for Evidence-Based Medicine

The **Centre for Evidence-Based Medicine** was established in Oxford in 1995 with the aim of promoting evidence-based health care to all offering effective and up-to-date decision-making in health care around the world.

It provides support and resources to doctors, clinicians, teachers and others interested in learning about Evidence Based Medicine (EBM).



# LEVELS OF SCIENTIFIC EVIDENCE

## Oxford Centre for Evidence-based Medicine Levels of Evidence (March 2009)

| Level     | Therapy/Prevention, Aetiology/Harm  |
|-----------|---|
| <b>1a</b> | SR (with homogeneity) of <b>RCTs</b>  |
| <b>1b</b> | Individual RCT (with narrow Confidence Interval)  |
| <b>1c</b> | All or none   |
| <b>2a</b> | SR (with homogeneity) of <b>cohort studies</b>  |
| <b>2b</b> | Individual cohort study (including low quality RCT; e.g., <80% follow-up)   |
| <b>2c</b> | "Outcomes" Research; Ecological studies   |
| <b>3a</b> | SR (with homogeneity) of <b>case-control studies</b>  |
| <b>3b</b> | Individual Case-Control Study   |
| <b>4</b>  | <b>Case-series</b> (and poor quality cohort and case-control studies)   |
| <b>5</b>  | <b>Expert opinion</b> without explicit critical appraisal, or based on physiology, bench research or "first principles" |





# What is **GRADE**?

- **GRADE** is a systematic and explicit approach to making judgements about quality of evidence and strength of recommendations.
- It was developed by the **Grading of Recommendations, Assessment, Development and Evaluations (GRADE)** Working Group, and it is now widely seen as the most effective method of linking evidence-quality evaluations to clinical recommendations.
- When placed alongside our existing intervention categorizations, **GRADE** gives clinicians a clear view of the evidence relating to key treatment interventions.





# How does it work?

**GRADE** addresses many of the perceived shortcomings of existing models of evidence evaluation. Crucially, when using GRADE, we rate evidence not study by study, but across studies for specific clinical outcomes.

The **GRADE** approach specifically assesses:

**Methodological** flaws within the component studies

**Consistency** of results across different studies

**Generalizability** of research results to the wider patient base

**How effective** the treatments have been shown to be.

Treatment comparisons are given **one of four GRADE scores** reflecting the **quality of the evidence** — high-, moderate-, low-, or very low-quality evidence.

## The final **GRADE** score

We use 4 categories of evidence quality based on the overall GRADE scores for each comparison: **high** (at least 4 points overall), **moderate** (3 points), **low** (2 points), and **very low** (one or less).




## NCCN

# Categories of Evidence and Consensus

- **Category 1:** Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
- **Category 2A:** Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
- **Category 2B:** Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
- **Category 3:** Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

**Table 1** Comparison of NCCN Categories of Evidence and Consensus and Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence

| NCCN categories of evidence   | Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of evidence |                |  |
|---|--|----------------|--|
|   | Recommendations  | Evidence level | Description  |
| Category 1: based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate    | A  | 1a             | Systematic reviews (with homogeneity) of randomized controlled trials  |
|   |  | 1b             | Individual randomized controlled trials (with narrow confidence interval)  |
|   |  | 1c             | All or none randomized controlled trials (all patients die before the application of treatment, and some patients survive after treatment; or some patients die before the application of treatment and no patient dies after treatment) |
| Category 2A: based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate  | B  | 2a             | Systematic reviews (with homogeneity) of cohort studies  |
|   |  | 2b             | Individual cohort study or low quality randomized controlled trials (e.g., <80% follow-up)   |
| Category 2B: based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate          |  |                |  |
|   |  | 3a             | Systematic review (with homogeneity) of case-control studies   |
| Category 3: based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate | C  | 3b             | Individual case-control study  |
|   |  | D              | 4  |
|   | 5  |                | Expert opinion or comment  |





# STATISTICAL DIFFERENCE $\neq$ CLINICAL DIFFERENCE



**CLINICAL  
JUDGMENT**

**STATISTICAL  
JUDGMENT**

